Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

ConditionHodgkin Lymphoma, Adult

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18+

SponsorNational Medical Research Radiological Centre of the Ministry of Health of Russia

About this trial

The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma

Eligibility criteria

Qualifiers

Newly-diagnosed histologically verified advanced stage (IIB-IV as per GHSG) classic Hodgkin lymphoma

No past history of autoimmune disease

Age > 18 years

Ejection fraction > 50%

Disqualifiers

Organ failure (e.g. creatinine > 2x ULN; ALT or AST > 5x ULN; bilirubin > 2x ULN; hemodynamic instability; respiratory failure > Grade 1)

Uncontrolled infection

Pregnancy

Inability to sign informed consent

Trial design

Treatments tested in this trial

Nivolumab
Doxorubicin
Vinblastine
Dacarbazine

Treatment groups

54 Participants

are divided into 1 treatment group

Sponsors and collaborators

National Medical Research Radiological Centre of the Ministry of Health of Russia

Lead sponsor

Source ClinicalTrials.gov